CING Stock Forecast: Cingulate, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.51

The median 12-month analyst price target for Cingulate, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$67.5M
Ticker Nerd rank
25/ 100
Median analyst target
$20
Analysts covering
4
Revenue$0.0
Operating income−$5.4M
Net income−$5.9M
Free cash flow−$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cingulate, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
25/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
66
Value
38
Accruals
37
Quality
36
Volatility
35
Revisions
31
Growth
28
Issuance
25

Momentum (66): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CING stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CING, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$8
Low
$20
Median
$44
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
24 Aug 2026Roth CapitalReiteratesBuy$10 → $9.00
20 Aug 2026Ascendiant CapitalMaintainsBuy$52 → $44
8 June 2026Ascendiant CapitalMaintainsBuy$55 → $52
26 May 2026HC Wainwright & Co.ReiteratesBuy—
8 Apr 2026Ascendiant CapitalMaintainsBuy—
23 Mar 2026Roth CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
19 Nov 2025Roth CapitalMaintainsBuy—
15 Oct 2025Roth CapitalMaintainsBuy—
22 Aug 2025Ascendiant CapitalMaintainsBuy—
27 May 2025Ascendiant CapitalMaintainsBuy—
19 May 2025Roth CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.MaintainsBuy—
10 Jan 2025Roth MKMInitiatesBuy—
20 Nov 2024Maxim GroupUpgradeBuy—
5 Jan 2024HC Wainwright & Co.MaintainsBuy—
22 Dec 2023Laidlaw & Co.DowngradeHold—
19 Dec 2023Maxim GroupDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CING.

Market Radar

This page is one stock. Monday covers all of them.

CING appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

CING analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
13.0×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−198.7%

Higher than 8% of US stocks

Return on assets
−66.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cingulate, Inc. has a market value of $67.5M and an enterprise value of $40.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$28.8M.

  • Diluted earnings per share, trailing twelve months: −$3.62.

  • Free cash flow in the twelve months to 30 June 2026: −$20.9M.

  • Shares outstanding: 13.9M.

  • Cingulate, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CING and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CINGCingulate, Inc.$67.5M25
GOSSGossamer Bio, Inc.$65.5M65
CRDFCardiff Oncology, Inc.$65.7M48
TNYATenaya Therapeutics, Inc.$65.3M50
PMVPPMV Pharmaceuticals, Inc.$66.1M56
PLYXPolaryx Therapeutics, Inc.$66.3M11
MNOVMediciNova, Inc.$64.4M88

Take a look at CING’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cingulate, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CING

What is the CING stock price forecast for 2026-2027?

The median 12-month analyst price target for Cingulate, Inc. is $20, with estimates ranging from $8 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CING stock a buy right now?

Of the 4 analysts covering Cingulate, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cingulate, Inc. 25 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CING?

As at 21 Nov 2026, Cingulate, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (66 of 100).

Will CING stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $20, and Ticker Nerd's factor model ranks Cingulate, Inc. 25 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CING stock forecast for 2030?

No analyst covering Cingulate, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CING are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $44 over the next 12 months.

What does Cingulate, Inc. do?

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings.

Company

About Cingulate, Inc.

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings. The company’s current pipeline includes CTx-1301, a dexmethylphenidate-based candidate for ADHD in children, adolescents, and adults, and CTx-2103, a buspirone-based formulation for anxiety. Cingulate also works on additional stimulant candidates within the same platform to address common psychiatric and behavioral conditions. Based in Kansas City, Kansas, Cingulate serves the biopharmaceutical market through specialized product development centered on chronic conditions that require consistent daily dosing and targeted drug release.

CEO Dr. Shane J. Schaffer Pharm.D. · 14 employees · United States · https://www.cingulate.com